Identification of novel potent and non-toxic anticancer, anti-angiogenic and antimetastatic rhenium complexes against colorectal carcinoma
作者:Joachim Delasoie、Aleksandar Pavic、Noémie Voutier、Sandra Vojnovic、Aurelien Crochet、Jasmina Nikodinovic-Runic、Fabio Zobi
DOI:10.1016/j.ejmech.2020.112583
日期:2020.10
were discovered to possess remarkable anticancer, anti-angiogenic and antimetastatic activity in vivo (zebrafish-human HCT-116 xenograft model), being effective at very low doses (1–3 μM). At doses as high as 250 μM the complexes did not provoke toxicity issues encountered in clinical anticancer drugs (cardio-, hepato-, and myelotoxicity). In vivo assays showed that the two compounds exceed the anti-tumor
同时针对肿瘤生长和血管形成的联合治疗被认为是结直肠癌(CRC)治疗的基石。然而,大多数临床抗癌药物的主要障碍是其对癌细胞的选择性活性弱和固有的内脏毒性,以及快速的耐药性发展。在我们发现有效抗CRC的新型选择性和无毒药物的努力中,我们设计,合成和表征了一系列具有增加的亲脂性的tri(I)基于三羰基的配合物。发现这些新型化合物中的两种在体内具有显着的抗癌,抗血管生成和抗转移活性(斑马鱼-人类HCT-116异种移植模型),以非常低的剂量(1-3μM)有效。在高达250μM的剂量下,复合物不会引起临床抗癌药物遇到的毒性问题(心脏,肝脏和骨髓毒性)。体内试验显示这两种化合物超过了临床药物顺铂和苹果酸舒尼替尼的抗肿瘤和抗血管生成活性,并显示出较大的治疗范围。